2014 Update of the drug resistance mutations in HIV-1
Annemarie M Wensing, Vincent Calvez, Huldrych F Günthard, Victoria A Johnson, Roger Paredes, Deenan Pillay, Robert W Shafer, Douglas D Richman, Annemarie M Wensing, Vincent Calvez, Huldrych F Günthard, Victoria A Johnson, Roger Paredes, Deenan Pillay, Robert W Shafer, Douglas D Richman
Abstract
This July 2014 edition of the IAS-USA drug resistance mutations list updates the figures last published in March 2013. The following mutations have been added to existing classes or drugs: K65E/N has been added to the bars for the nucleoside and nucleotide analogue reverse transcriptase inhibitors (nRTIs) abacavir, didanosine, emtricitabine, lamivudine, stavudine, and tenofovir; L100I has been added to the bar for the nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) rilpivirine; and F121Y has been added to the bars for the integrase strand transfer inhibitors (InSTIs) dolutegravir, elvitegravir, and raltegravir. With regard to protease inhibitors (PIs), it cannot be excluded that drug resistance may be selected for outside the protease encoding region.
Conflict of interest statement
Financial affiliations in the past 12 months: The authors (listed alphabetically) disclose the following affiliations with commercial organizations that may have interests related to the content of this article: Dr Calvez has served on advisory boards for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Pharmaceuticals, Inc, Pfizer, Inc, Roche, and ViiV Healthcare. Dr Günthard has served as an advisor and/or consultant for Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Novartis, Pfizer, Inc, Roche, and Tibotec Therapeutics, with all compensation going to his institution, University Hospital of Zurich. He has received unrestricted research and educational grants to his institution from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck Sharp & Dohme, and Roche; has served on a data and safety monitoring board for Merck Sharp & Dohme; and has received travel grants from Bristol-Myers Squibb and Gilead Sciences, Inc. Dr Johnson has received research support from Abbott Molecular, Roche Molecular Diagnostics, and Siemens Healthcare Diagnostics, Inc. Dr Paredes has received research grants awarded to IrsiCaixa and Lluita Contra la SIDA Foundations from Gilead Sciences, Inc, and ViiV Healthcare. Dr Pillay has no relevant financial affiliations to disclose. Dr Richman has been a consultant to Bristol-Myers Squibb, Chimerix, Gen-Probe Inc, Gilead Sciences, Inc, Sirenas, Prism, and Monogram Biosciences, Inc. He owns stock from Chimerix. Dr Shafer has served as a consultant or advisor for Celera and has received grants from Bristol-Myers Squibb F. Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, and Merck & Co, Inc. Dr Wensing has served on advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc; has received grants from Janssen Pharmaceuticals, Inc, and ViiV Healthcare; and has received travel, accommodation, or meeting expenses from Bristol-Myers Squibb and Virology Education.
Source: PubMed